Department of Ophthalmology, Van Training and Research Hospital, 65000, Van, Turkey.
Department of Ophthalmology, Faculty of Medicine, Fırat University, 23119, Elazig, Turkey.
Int Ophthalmol. 2021 Aug;41(8):2905-2912. doi: 10.1007/s10792-021-01851-9. Epub 2021 Apr 17.
To investigate the protective effect of filgotinib in endotoxin-induced uveitis model in rats.
This study used 24 Wistar Albino rats. Group I (control group) included the healthy controls; in Group II (sham group), only 300 µg/kg intraperitoneal (ip) lipopolysaccharide (LPS) was administered; and in Group III (treatment group), 3 mg/kg/day filgotinib was administered orally for 10 days followed by 300 µg/kg ip LPS. In all groups, clinical activity scores were evaluated after 24 h. Moreover, histopathological and immunological examinations were performed.
In Groups I, II, and III, the mean clinical activity and histopathological examination scores were 0.00, 3.25 ± 0.70, and 1.89 ± 0.60 and 0.00, 2.88 ± 1.12, and 1.44 ± 0.52, respectively. The clinical activity and histopathological examination scores were significantly increased in the sham group compared to the control group (p < 0.05); these findings were significantly reduced in the treatment group (p < 0.05). The mean TNF-α and IL-6 ELISA levels in all groups were 50.20 ± 3.24, 59.87 ± 2.98, and 54.34 ± 4.62 and 30.88 ± 1.79, 36.77 ± 1.21, and 33.66 ± 1.86, respectively. The TNF-α and IL-6 ELISA levels were significantly decreased in the treatment group compared to the sham group (p < 0.05); there was no significant difference between the treatment group and the control group (p = 0.105, p = 0.067, respectively) CONCLUSION: Filgotinib may be an alternative treatment option in preventing the development of noninfectious uveitis.
研究昔布替尼在大鼠内毒素性葡萄膜炎模型中的保护作用。
本研究使用 24 只 Wistar 白化大鼠。第 I 组(对照组)包括健康对照;第 II 组(假手术组)仅给予 300μg/kg 腹腔内(ip)脂多糖(LPS);第 III 组(治疗组)给予 3mg/kg/天昔布替尼口服 10 天,然后给予 300μg/kg ip LPS。在所有组中,在 24 小时后评估临床活动评分。此外,还进行了组织病理学和免疫学检查。
在 I、II 和 III 组中,平均临床活动和组织病理学检查评分分别为 0.00、3.25±0.70 和 1.89±0.60 以及 0.00、2.88±1.12 和 1.44±0.52。与对照组相比,假手术组的临床活动和组织病理学检查评分显著升高(p<0.05);治疗组的评分显著降低(p<0.05)。所有组的 TNF-α 和 IL-6 ELISA 水平分别为 50.20±3.24、59.87±2.98 和 54.34±4.62 以及 30.88±1.79、36.77±1.21 和 33.66±1.86。与假手术组相比,治疗组的 TNF-α 和 IL-6 ELISA 水平显著降低(p<0.05);与对照组相比,治疗组与对照组之间无显著差异(p=0.105,p=0.067)。
昔布替尼可能是预防非感染性葡萄膜炎发展的一种替代治疗选择。